MedTrace Logo

A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis

NCT05120297 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 452

Last updated 2023-03-02

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled, multicentered phase III clinical study to evaluate the efficacy and safety of AK101 in the treatment of subjects with moderate-to-severe plaque psoriasis.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

AK101

Subjects will receive AK101 subcutaneous injection at week 0 and week 4, and will follow up to week 16.

DRUG

Placebo

Subjects will receive placebo subcutaneous injection at week 0 and week 4, and will follow up to week 16.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-29
Primary Completion
2022-09-29
Completion
2022-09-29

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05120297 on ClinicalTrials.gov